Taro Koya

Empagliflozin suppresses mitochondrial reactive oxygen species generation and mitigates the inducibility of atrial fibrillation in diabetic rats

Takuya Koizumi, Masaya Watanabe, Takashi Yokota et al. · Frontiers in Cardiovascular Medicine · 2023 · 58 citations · Full text

Life Sciences, Cardiology, Pharmacology +17

Empagliflozin attenuates arrhythmogenesis in diabetic cardiomyopathy by normalizing intracellular Ca²⁺ handling in ventricular cardiomyocytes

Takahide Kadosaka, Masaya Watanabe, Hiroyuki Natsui et al. · American Journal of Physiology-Heart and Circulatory Physiology · 2023 · 39 citations

Medicine, Cardiology, Pharmacology +17

Applicability of New Proposed Criteria for Iron Deficiency in Japanese Patients with Heart Failure

Atsushi Tada, Toshiyuki Nagai, Taro Koya et al. · ESC Heart Failure · 2022 · 18 citations · Full text

Medicine, Cardiology, Health Assessment +16

Fragmented QRS on 12-lead electrocardiogram predicts long-term prognosis in patients with cardiac sarcoidosis

Hikaru Hagiwara, Masaya Watanabe, Takahide Kadosaka et al. · Heart and Vessels · 2023 · 13 citations

Medicine, Cardiology, Internal Medicine +13

Differential Prognostic Impact of Atrial Fibrillation in Hospitalized Heart Failure Patients With Preserved Ejection Fraction According to Coronary Artery Disease Status　― Report From the Japanese Nationwide Multicenter Registry ―

Taro Temma, Toshiyuki Nagai, Masaya Watanabe et al. · Circulation Journal · 2020 · 12 citations · Full text

Medicine, Cardiology, Clinical Cardiology +9